Amneal Pharmaceuticals
AMRX
139 hedge funds and large institutions have $484M invested in Amneal Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 32 increasing their positions, 52 reducing their positions, and 19 closing their positions.
69% more call options, than puts
Call options by funds: $1.74M | Put options by funds: $1.03M
68% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 19
41% more capital invested
Capital invested by funds: $342M → $484M (+$142M)
9% more funds holding
Funds holding: 127 → 139 (+12)
2.25% more ownership
Funds ownership: 66.78% → 69.03% (+2.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
38% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 52
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$4.49M |
| 2 |
EP
Eversept Partners
New York
|
+$3.65M |
| 3 |
TAM
THB Asset Management
Norwalk,
Connecticut
|
+$2.68M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$2.66M |
| 5 |
SGH
Sivik Global Healthcare
Greenwich,
Connecticut
|
+$2.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$5.57M |
| 2 |
BlackRock
New York
|
-$2.53M |
| 3 |
Goldman Sachs
New York
|
-$1.44M |
| 4 |
Bank of New York Mellon
New York
|
-$825K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$799K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EI
151
Ellevest Inc
New York
| – | -$1K | -160 | Closed |
|
152
Fidelity Investments
Boston,
Massachusetts
| – | -$91 | -22 | -22% |
|
AMRX Hedge Fund Activity: Q2 2020 in Review
139 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q2 2020, worth a combined $484M — up 41% from $342M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new AMRX positions and 19 closed out — a net gain of 13 holders — while 32 added to existing stakes and 52 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $4.49M. The largest seller was Federated Hermes, cutting an estimated $5.57M.
- 139 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q2 2020, up from 127 in Q1 2020.
- Funds reported $484M of Amneal Pharmaceuticals stock for Q2 2020, up 41% quarter-over-quarter.
- 32 funds opened new Amneal Pharmaceuticals positions in Q2 2020 and 19 closed out, a net change of +13 holders.
- The largest Amneal Pharmaceuticals buyer in Q2 2020 was Arrowstreet Capital, an estimated $4.49M added.
- The largest Amneal Pharmaceuticals seller in Q2 2020 was Federated Hermes, an estimated $5.57M sold.
Based on aggregated 13F filings for Q2 2020.